Orthotopic liver transplantation as a rescue operation for recurrent hepatocellular carcinoma after partial hepatectomy

Table 1 Demographic and clinical data

Factors	Rescue OLT group (n = 15)	De novo OLT group (n = 62)
Age (yr)1	50.0 (46.0-55.0)	49.0 (44.0-55.0)
Male, No. (%)	14 (93.3)	51 (82.3)
Excessive alcohol use, No. (%)	5 (33.3)	13 (21.0)
Tobacco use, No. (%)	7 (46.7)	52 (83.9)
Family history of liver cancer, No. (%)	3 (20.0)	8 (12.9)
Hepatitis B infection, No. (%)	15 (100.0)	57 (91.9)
Diabetes, No. (%)	2 (13.3)	7 (11.3)
Liver cirrhosis, No. (%)	15 (100.0)	60 (96.8)
Months from tumor detection to OLT1	1.0 (1.0, 3.0)	2.0 (1.0, 3.0)
Child-Pugh Score, No. (%)
A	7 (46.7)	39 (62.9)
B	6 (40.0)	23 (37.1)
C	2 (13.3)	0 (0.0)
UICC pTNM tumor staging1	3.0 (3.0, 3.0)	3.0 (3.0, 3.0)
Total bilirubin (&mgr;mol/L)1	22.8 (15.0, 54.6)	32.1 (23.0, 55.4)
Direct bilirubin (&mgr;mol/L)1	10.4 (5.8, 35.3)	14.4 (9.8, 29.5)
Albumin (g/L)1	35.3 (32.1, 42.1)	34.5 (32.0, 37.6)
Prealbumin (g/L)1	12.7 (9.3, 15.3)	10.3 (6.9, 14.5)
Alanine aminotransferase (U/L)1	90.1 (37.7, 183.9)	48.9 (37.8, 91.7)
Asparate aminotransferase (U/L)1	85.4 (36.5, 150.0)	65.5 (47.1, 99.4)
Prothrombin time (s)1	14.5 (13.3, 17.9)	15.2 (13.4, 17.8)
Activated partial thromboplastin time (s)1	34.7 (31.8, 38.0)	34.8 (30.7, 41.3)
OLT operating room time (h)1	8.0 (7.2, 8.1)	6.8 (5.7, 7.7)
OLT anhepatic time (min)1	65.0 (60.0, 81.0)	62.0 (56.0, 74.0)
OLT intra-op bleeding (L)1	2.0 (1.5, 2.3)	1.5 (1.2, 2.0)
OLT intra-op transfusion (L)1	1.6 (1.0, 2.0)	0.8 (0.4, 1.4)
OLT post-op transfusion (L)1	1.2 (0.8, 2.0)	0.4 (0.0, 1.4)
Pre-OLT α-fetoprotein (U/L)1	7.5 (4.9, 27.1)	362.6 (20.4, 3480.0)
Post-OLT α-fetoprotein (U/L)1	5.3 (4.1, 10.9)	15.7 (5.4, 120.4)
Change in α-fetoprotein after OLT1	4.2 (0.8, 21.8)	337.9 (13.3, 3023.5)
Postoperative histopathology1
Size of largest tumor in diameter (cm)1	3.0 (1.5, 6.0)	3.6 (2.5, 6.0)
Number of tumor1	1.0 (1.0, 4.0)	1.0 (1.0, 2.0)
Histology differentiation of tumor, No. (%)
Moderate	8 (53.3)	9 (14.5)
Poor	7 (46.7)	53 (85.5)
Tumor vascular invasion, No. (%)
None	5 (33.3)	26 (41.9)
Microvascular	8 (53.3)	33 (53.2)
Macrovascular	2 (13.3)	3 (4.8)
Tumor in right lobe, No. (%)	13 (86.7)	53 (85.5)
Post-OLT treatment, No. (%)
None	1 (6.7)	2 (3.2)
Chemotherapy	14 (93.3)	60 (96.8)
Time of follow-up (mo)1	18.0 (12.0, 24.0)	21.0 (14.0, 32.0)

¹Statistics presented are medians (Q25, Q75).